SEL: Clinical Trials

4 completed, 2 terminated. 4 Phase 2, 2 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	4	Completed 4
Phase 3	2	Terminated 2

Follow SEL: new trials by email Literature Review of SEL trials Research Report on SEL

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease SEL, Placebo - Diabetic Kidney Disease	Phase 2	Completed	Gilead Sciences	384	2019-07-24	2022-12-21
Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) SEL, FIR, CILO - Nonalcoholic Steatohepatitis	Phase 2	Completed	Gilead Sciences	395	2018-03-21	2020-12-03
Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis SEL, Placebo to match SEL 6 mg, Placebo to match SEL 18 mg - Nonalcoholic Steatohepatitis	Phase 3	Terminated	Gilead Sciences	808	2017-02-13	2020-06-29
Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) SEL, Placebo to match SEL 6 mg, Placebo to match SEL 18 mg - Nonalcoholic Steatohepatitis	Phase 3	Terminated	Gilead Sciences	883	2017-01-30	2020-05-07
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH) SEL, FIR, CILO - Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease (NAFLD)	Phase 2	Completed	Gilead Sciences	220	2016-06-13	2022-03-16
Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3 SEL, SIM - Non-Alcoholic Steatohepatitis (NASH)	Phase 2	Completed	Gilead Sciences	72	2015-06-08	2019-06-26

Conditions studied

Non-alcoholic Fatty Liver Disease (5)  ·  Diabetic Nephropathies (1)  ·  Fibrosis (1)

Sponsors

Gilead Sciences (6)

Countries

United States (6)  ·  Canada (5)  ·  New Zealand (5)  ·  Australia (4)  ·  Hong Kong (3)  ·  Japan (3)  ·  Puerto Rico (3)  ·  Austria (2)  ·  Belgium (2)  ·  France (2)  ·  Germany (2)  ·  India (2)  ·  Israel (2)  ·  Italy (2)  ·  Mexico (2)

Results publications

PMID 30639779, PMID 30779990, PMID 31271665, PMID 32147362, PMID 33307033, PMID 36750244, PMID 33169409, PMID 34999207, PMID 39018154

NIH funding

2016 (2), 2018 (1)